Stryker Co. (NYSE:SYK) Shares Bought by apricus wealth LLC

apricus wealth LLC boosted its stake in shares of Stryker Co. (NYSE:SYK) by 17.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,154 shares of the medical technology company’s stock after buying an additional 322 shares during the period. apricus wealth LLC’s holdings in Stryker were worth $802,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Norges Bank acquired a new position in Stryker during the fourth quarter worth $1,710,744,000. GAMMA Investing LLC lifted its stake in shares of Stryker by 43,226.8% in the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock valued at $772,390,000 after purchasing an additional 2,070,133 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $353,394,000. FMR LLC lifted its stake in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock valued at $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Finally, Proficio Capital Partners LLC lifted its stake in shares of Stryker by 52,520.8% in the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock valued at $214,660,000 after purchasing an additional 595,061 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Roth Mkm boosted their price objective on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a report on Friday, May 2nd. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Monday, May 5th. BTIG Research set a $403.00 price objective on Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Finally, Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $427.30.

Stryker Trading Down 1.0%

SYK opened at $381.03 on Thursday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market cap of $145.43 billion, a P/E ratio of 49.10, a PEG ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The business’s 50-day simple moving average is $371.23 and its 200-day simple moving average is $375.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.50 EPS. As a group, equities research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is presently 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.